MBG453B
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $656,277 | 19 | 2 |
| 2019 | $98,713 | 14 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $754,990 | 33 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II MULTI-CENTER STUDY OF INTRAVENOUS MBG453 ADDED TO HYPOMETHYLATING AGENTS IN ADULT SUBJECTS WITH INTERMEDIATE, HIGH OR VERY HIGH RISK MYELODYSPLASTIC SYNDROME (MDS) AS PER IPSS-R CRITERIA (STIMULUS-MD | Novartis Pharmaceuticals Corporation | $705,398 | 0 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III MULTI-CENTER STUDY OF AZACITIDINE WITH OR WITHOUT MBG453 FOR THE TREATMENT OF PATIENTS WITH INTERMEDIATE, HIGH OR VERY HIGH RISK MYELODYSPLASTIC SYNDROME (MDS) AS PER IPSS-R, OR CHRONIC MYELOMONOCYT | Novartis Pharmaceuticals Corporation | $49,246 | 0 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $347.00 | 2 |
Top Doctors Receiving Payments for MBG453B
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Houston, TX | $754,643 | 31 |
| Amer Zeidan | Hematology & Oncology | New Haven, CT | $204.00 | 1 |
| , MD | Hematology & Oncology | Miami, FL | $143.00 | 1 |
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $754,990
Product Information
- Type Drug
- Total Payments $754,990
- Total Doctors 2
- Transactions 33
About MBG453B
MBG453B is a drug associated with $754,990 in payments to 2 healthcare providers, recorded across 33 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2019 to 2020. In 2020, $656,277 was paid across 19 transactions to 2 doctors.
The most common payment nature for MBG453B is "Unspecified" ($754,990, 100.0% of total).
MBG453B is associated with 3 research studies, including "A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II MULTI-CENTER STUDY OF INTRAVENOUS MBG453 ADDED TO HYPOMETHYLATING AGENTS IN ADULT SUBJECTS WITH INTERMEDIATE, HIGH OR VERY HIGH RISK MYELODYSPLASTIC SYNDROME (MDS) AS PER IPSS-R CRITERIA (STIMULUS-MD" ($705,398).